Follow us on LinkedIn

Functional Microbiome Therapies

Based on our research, we believe that the common denominator underlying each intestinal microbiome is a network of interconnected, interdependent and metabolic functions that are essential for the host and the microbiome.
See more about our perspective on microbiome function

PharmaBiome has developed unique technologies to access the entire range of intestinal bacteria for the design and production of function-based consortia at scale.
Read about our differentiated technologies

We are a pre-clinical stage spinoff from the ETH Zurich, combining key expertise in microbiology, biotechnology and the molecular disease mechanisms that involve the microbiome.
See the expertise of our board, advisors and operational team

Researcher studying bacteria in microscope

Our Vision

We unlock the therapeutic potential of the microbiome through our deep understanding of microbial function, host-microbiome interactions and disease-specific dynamics, enabling us to discover and develop therapeutics and bring the hope for cure to patients.

We strive to become the leading global experts in the development of bacterial consortia based on mixed cultures. Our mission is to unlock the therapeutic potential of the microbiome through a deep understanding of its function and the disease-specific dynamics.

Why Microbiome Function Matters

Research informs our belief that the smallest relevant biological unit is the function, delivered by intestinal bacteria, and not the bacterial strain. These bacteria interact in a complex functional network to achieve a metabolically balanced microbiome.

more about function

Science of the Microbiome as a Network

The human microbiome fulfills a variety of functions. Each function is encoded in a set of bacteria that each have several functions under different circumstances. A bacterial consortium needs to be versatile, balanced and cover all the essential functions.

more about science

Our approach

We take a bottom-up approach and engineer bacterial consortia based on their metabolic interactions. Our deep understanding of function drives the selection of individual strains to be assembled and co-cultured with our groundbreaking technology.

more about our approach


Microbiome therapies go beyond FMT and are targeted to introduce a functionality. Starting with the biology of a specific disease, a tailored consortium of bacteria is mixed and co-cultured to reverse a dysbiosis.

more about therapies


PharmaBiome featured on SRF Einstein

read more

PharmaBiome among the TOP 100 Swiss startups

read more

PharmaBiome Welcomes New Board Members and Raises CHF 1.75 Million Capital

PharmaBiome announces the election of two new board members. To bridge to a planned Series A financing, CHF 1.75 Mio were raised.

read more

PharmaBiome is finalist of ZKB Pionierpreis 2020

Our pioneering efforts are awarded a price! PharmaBiome AG is proud to be a finalist of the ZKB Pionierpreis 2020.

read more

BaseLaunch finances PharmaBiome

We are proud to receive this prestigious grant and are eager to turn our learnings from this great program into action.

read more

PharmaBiome selected for ZKB Pionierpreis 2020

PharmaBiome AG is among the Top Ten startups selected for the ZKB Pionierpreis 2020

read more

PharmaBiome selected for BaseLaunch

PharmaBiome is proud to be among the 15 companies selected for the BaseLaunch Accelerator Program.

read more

PharmaBiome recognized by De Vigier foundation

PharmaBiome is one of the winners at the 2019 De Vigier Foundation Awards, recognizing its leadership in developing microbiome based therapies.

read more

World IBD Day reminds us of the high remaining unmet medical need

For IBD Day 2019 we have supported a video artist who sheds light on the unmet medical need. Addressing the microbiome may open the door to a curative therapy.

read more

Seal of Excellence (Horizon 2020)

PharmaBiome was awarded with the seal of excellence from the European Commission Horizon2020 programm …

read more




PharmaBiome AG
Wagistrasse 27
8952 Schlieren
UID CHE-190.589.234